Light-inducible base editing enable precise gene regulation

A new light-inducible RNA base editing tool, padCas13, combines the specificity of CRISPR-Cas13 with the control of light activation and allows for precise, reversible RNA targeting and degradation in mammalian cells, both in vitro and in vivo.

By: Gorm Palmgren - Jan. 23, 2024

#CRISPRMED24

The padCas13 editor can effectively edit A-to-I and C-to-U RNA bases, targeting disease-relevant transcripts. Photoactivatable base editing represents a significant advancement in CRISPR technology, as it allows for fine-tuning gene expression and post-translational modifications without permanent changes to the genome. This method is particularly relevant for diseases where transient gene expression modulation can have therapeutic benefits.

A crucial part of padCas13 is the Magnet system that comprises a positively and a negatively charged Magnet protein. These proteins are designed to quickly heterodimerize in response to light, thereby activating the Cas13 nuclease.

The study was conducted by Won Do Heo and co-workers from the Korea Advanced Institute of Science and Technology (KAIST). Their article titled "Programmable RNA base editing with photoactivatable CRISPR-Cas13" was published yesterday in Nature Communications, and you can read it here.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagMissing linksHashtagNewsHashtagCRISPR Therapeutics AG

News: Light-inducible base editing enable precise gene regulation
News: Light-inducible base editing enable precise gene regulation
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine